Enanta’s Abbvie Partnership Is Going Places But It’s Still Overvalued

Enanta’s Abbvie Partnership Is Going Places But It’s Still Overvalued

[at Seeking Alpha] – There’s plenty to be excited about regarding the recently listed Enanta Pharmaceuticals ( ENTA ). Its lead compound, ABT-450, is a component of Abbvie’s ( ABBV ) promising hepatitis C virus (HCV) combination … more

View todays social media effects on ABBV

View the latest stocks trending across Twitter. Click to view dashboard

Share this post

Comments (0)